CDK46 Inhibitors Carry Consistent Benefit Across HRHER2 Breast Cancer Settings

CDK4/6 Inhibitors Carry Consistent Benefit Across HR+/HER2- Breast Cancer Settings

11:24 EST 27 Feb 2019 | OncLive

Joseph F. Stilwill, MD, shares insight on the clinical benefit seen with CDK4/6 inhibitors in patients with advanced HR-positive, HER2-negative breast cancer and highlights ongoing research aimed at overcoming acquired resistance.

More From BioPortfolio on "CDK4/6 Inhibitors Carry Consistent Benefit Across HR+/HER2- Breast Cancer Settings"